Overview

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Status:
Completed

Trial end date:
2020-05-21

Target enrollment:

Participant gender:

Summary

This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan